Table 3.
Factors Associated with Longitudinal Scores for Self-Reported Cognitive Problems1
| Fact-Cog Total | Fact-Cog PCI | |
|---|---|---|
| Covariates | β (SE) | β (SE) |
| Age, per 1 year increase | −.33 (−.87 – .22) | −.26 (−.62 – .09) |
| CogAge vs TLC | −6.40 (−13.5 – .66) | −1.73 (−6.31 – 2.85) |
| High school vs <=HS education | 5.81 (−.76 – 12.38) | 1.46 (−2.76 – 5.67) |
| IADL, per increase in limitations | −3.42 (−5.96 - −.89)** | −2.01 (−3.67 - −.36)* |
| Hormone Therapy (Yes versus No) | 3.37 (−1.81 – 8.55) | 1.33 (−2.05 – 4.71) |
| Impact of Taxanes | ||
| Taxane vs. non taxane regimen | 3.14 (−3.19 – 9.48) | 2.37 (−1.74 – 6.49) |
| Time effect, pre-treatment to 12-months | −4.57 (−7.52 - −1.62)** | −3.65 (−5.55 - −1.75)*** |
| Taxane group × pre-treatment to 12-months | .79 (−5.14 – 6.74) | .54 (−3.25 – 4.32) |
| Time effect, 12- to 36-months | 1.59 (−.51 – 3.69) | .89 (−.47 – 2.24) |
| Taxane group × 12- to 36-months | −2.46 (−6.51 – 1.60) | −.99 (−3.62 – 1.63) |
*
p < .05,
**
p < .01,
***
p < .001
1
Results for piecewise multilevel models modeling change in self-reported cognitive performance. Sample reference group is TLC; Education reference group is high school completion; treatment group reference is chemotherapy with taxane.